Sensorion (FRA:RFM) ROE % Adjusted to Book Value: -26.99% (As of Dec. 2025)


FRA:RFM Sensorion SA FRA:RFM
24 GF Score
Price €0.23
! 1 Warning Sign
View Full Analysis

What is Sensorion ROE % Adjusted to Book Value?

Sensorion FRA:RFM +17.11% 24 ROE % Adjusted to Book Value is -26.99% as of Dec. 2025. GuruFocus rates FRA:RFM with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.

Sensorion's ROE % for the quarter that ended in Dec. 2025 was -52.91%. Sensorion's PB Ratio for the quarter that ended in Dec. 2025 was 1.96. Sensorion's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -26.99%.

Sensorion ROE % Adjusted to Book Value Related Terms

Sensorion ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Sensorion's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sensorion ROE % Adjusted to Book Value Chart

Sensorion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.96 -59.65 -36.53 -19.95 -25.75

Sensorion Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.39 -19.43 -12.57 -32.41 -26.99

FRA:RFM vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Sensorion's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sensorion ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sensorion's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Sensorion's ROE % Adjusted to Book Value falls into.


FRA:RFM
24GF Score
Sensorion SA FRA:RFM
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sensorion ROE % Adjusted to Book Value Calculation

Sensorion's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-50.47% / 1.96
=-25.75%

Sensorion's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-52.91% / 1.96
=-26.99%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -26.99% mean?
Sensorion (FRA:RFM) has a ROE % Adjusted to Book Value of -26.99% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sensorion and its competitors.
Is Sensorion's ROE % Adjusted to Book Value too high?
Sensorion's current ROE % Adjusted to Book Value is -26.99%. Overall, Sensorion has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Sensorion's ROE % Adjusted to Book Value compare to VRTX and REGN?
Sensorion's ROE % Adjusted to Book Value of -26.99% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sensorion and its competitors. Sensorion's current ROE % Adjusted to Book Value is -26.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensorion stock overvalued right now?
Sensorion (FRA:RFM) has a current ROE % Adjusted to Book Value of -26.99%. The current ROE % Adjusted to Book Value is -26.99%. Sensorion's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Sensorion (FRA:RFM), the current ROE % Adjusted to Book Value is -26.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sensorion Business Description

Other Exchanges ALSEN:FranceRFM:Germany
Address 375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders. The SENS501 (OTOF-GT) targets deafness caused by mutations of the gene encoding for otoferlin and is currently developed in a Phase 1/2 clinical study, and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. The company's pipeline programs are OTOF-GT (SENS-501), GJB2-GT, GJB2-GT, GJB2-GT, TREAT AND PREVENT, SENS-401 COCHLEAR, SENS-401 CIO, and SENS-401 SSNHL.
24GF Score

Get the complete analysis for FRA:RFM

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.23
Price